Crossmark

Cetuximab plus capecitabine every three weeks as first-line maintenance therapy for RAS/BRAF wild-type metastatic colorectal cancer: a phase Ib dose-escalation study

Crossref DOI link: https://doi.org/10.1038/s41698-026-01429-7

Published Online: 2026-04-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xie, Xiaoyu

Lin, Ziqin

Li, Weiwei

Xie, Yuqian

Zhang, Jianwei

Hu, Huabin

Li, Shanshan

Zhai, Xiaohui

Shi, Lishuo

Deng, Yanhong
Funding

Funding for this research was provided by:

Beijing Bethune Charitable Foundation (2021-YJ-088-J)

Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0520304)

National Science Fund for Distinguished Young Scholars (82425045)

National Natural Science Foundation of China (82272800)
License Information

Text and Data Mining valid from 2026-04-24

Accepted Manuscript valid from 2026-04-24
More Information

Article History

Received: 9 January 2026

Accepted: 7 April 2026

First Online: 24 April 2026

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below